Dihexa
PeptideCompounding status of Dihexa — FDA 503A bulks-list standing, PCAC review history, and state overlays. Each entry links to its source; entries marked reported rest on trade-press coverage until the FDA primary record posts.
Current federal standing
Not compoundable under 503A
Dihexa is not on the 503A Bulks List. FDA has scheduled it for the next Pharmacy Compounding Advisory Committee review — by the end of February 2027 (exact date not yet posted). FDA PCAC ↗
Federal history
No federal status has been published for Dihexa yet. We’re monitoring the Federal Register and FDA/PCAC; a standing appears here only with its source document.
State overlays
No state-specific position on Dihexa tracked yet. State boards hold independent authority; legislation is monitored via LegiScan and board positions are added as they are verified.
Track Dihexa changes
Get the free weekly Brief — FDA and state moves on peptide & GLP-1 compounding, with the source and the date. Members are alerted for their states as soon as a change is published.
Get the free Brief →← All substances · Informational monitoring from public government sources — not legal or medical advice. No efficacy claims.